Overview
Yukino Oshima practices practicing medicine in Oyaguchi, Japan.
Her clinical expertise encompasses Acute Pain, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, and Hemolysis.
She is actively involved in clinical research, co-authoring 9 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Yukino Oshima
Is Yukino Oshima a top-rated expert for Acute Pain?
MediFind is an objective health platform that identifies experts based on real-world data. Yukino Oshima is classified as an Experienced expert for Acute Pain, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Yukino Oshima participate in research or clinical trials?
Yes. Yukino Oshima has published 9 articles and abstracts on conditions like Acute Pain. You can view a list of Yukino Oshima's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Acute PainMs. Oshima isExperienced. Learn about Acute Pain.
- HemolysisMs. Oshima isExperienced. Learn about Hemolysis.
- Pancreatic CancerMs. Oshima isExperienced. Learn about Pancreatic Cancer.
- Pancreatic Ductal AdenocarcinomaMs. Oshima isExperienced. Learn about Pancreatic Ductal Adenocarcinoma.